📊 AXGN Key Takeaways
Is Axogen, Inc. (AXGN) a Good Investment?
Axogen demonstrates strong revenue growth (20.2% YoY) and exceptional gross margins (75.2%), validating product-market fit in the electromedical device sector. However, the company is deeply unprofitable with a -$19.6M net loss and negative free cash flow (-$1.2M), while EPS deteriorated 47.8% YoY, indicating failed operational leverage despite revenue expansion. Without evidence of cost control or a path to profitability, the fundamental earnings deterioration presents material investment risk.
Axogen shows strong top-line momentum and attractive unit economics, with 20.2% revenue growth and a 74.3% gross margin indicating a differentiated, high-value product portfolio. However, the business is not yet consistently profitable, with negative operating income, worsening net losses, weak interest coverage, and slightly negative free cash flow limiting the quality of that growth. The balance sheet and liquidity are solid enough to support execution, but fundamentals still require proof of durable earnings conversion.
Axogen, Inc. Key Strengths (AXGN)
- Strong revenue growth of 20.2% YoY demonstrates solid market demand and commercial traction
- Exceptional gross margins of 75.2% indicate strong pricing power and product differentiation
- Fortress balance sheet with $82.7M cash, zero debt, and 7.1x current ratio provides 3+ years of operational runway
- Revenue growth is strong at 20.2% YoY, showing continued commercial adoption
- Gross margin of 74.3% suggests strong pricing power and favorable product economics
- Liquidity is robust, with a 5.11x current ratio, 3.31x quick ratio, and moderate 0.38x debt/equity
AXGN Stock Risks: Axogen, Inc. Investment Risks
- Significant operating losses (-$2.8M) and net losses (-$19.6M) with no visible profitability inflection point
- Negative free cash flow (-$1.2M) despite 20% revenue growth indicates broken unit economics or severely uncontrolled cost structure
- Deteriorating EPS (-47.8% YoY) demonstrates worsening profitability trend and absence of operational leverage from revenue scaling
- Net income deteriorated 57.6% YoY, showing profitability remains fragile
- Operating margin is still negative at -3.5%, so scale has not yet translated into sustained earnings
- Interest coverage is negative and free cash flow remains below zero, increasing execution risk if losses persist
Key Metrics to Watch
- Operating income trend - must improve sequentially to demonstrate cost discipline
- Free cash flow conversion - must turn sustainably positive within next 2-3 quarters
- Operating expense ratio to revenue - must demonstrate expense deceleration as revenue scales
- Operating margin and net income trend toward sustained profitability
- Free cash flow and operating cash flow conversion as revenue grows
Axogen, Inc. (AXGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.10x current ratio provides a solid financial cushion.
AXGN Profit Margin, ROE & Profitability Analysis
AXGN vs Healthcare Sector: How Axogen, Inc. Compares
How Axogen, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Axogen, Inc. Stock Overvalued? AXGN Valuation Analysis 2026
Based on fundamental analysis, Axogen, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Axogen, Inc. Balance Sheet: AXGN Debt, Cash & Liquidity
AXGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Axogen, Inc.'s revenue has grown significantly by 77% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.51 indicates the company is currently unprofitable.
AXGN Revenue Growth, EPS Growth & YoY Performance
AXGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $48.6M | -$3.8M | $-0.08 |
| Q3 2025 | $48.6M | $708.0K | $0.01 |
| Q2 2025 | $47.9M | $579.0K | $0.01 |
| Q1 2025 | $41.4M | -$3.8M | $-0.08 |
| Q3 2024 | $41.3M | -$1.9M | $-0.04 |
| Q2 2024 | $38.2M | -$1.9M | $-0.04 |
| Q1 2024 | $36.7M | -$6.6M | $-0.15 |
| Q3 2023 | $37.0M | -$4.1M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Axogen, Inc. Dividends, Buybacks & Capital Allocation
AXGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Axogen, Inc. (CIK: 0000805928)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 12, 2026 | 4 | xslF345X06/wk-form4_1778616387.xml | View → |
| May 8, 2026 | 4 | xslF345X06/wk-form4_1778270876.xml | View → |
| May 8, 2026 | 4 | xslF345X06/wk-form4_1778270855.xml | View → |
| May 8, 2026 | 4 | xslF345X06/wk-form4_1778270821.xml | View → |
| May 8, 2026 | 4 | xslF345X06/wk-form4_1778270803.xml | View → |
❓ Frequently Asked Questions about AXGN
What is the AI rating for AXGN?
Axogen, Inc. (AXGN) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AXGN's key strengths?
Claude: Strong revenue growth of 20.2% YoY demonstrates solid market demand and commercial traction. Exceptional gross margins of 75.2% indicate strong pricing power and product differentiation. ChatGPT: Revenue growth is strong at 20.2% YoY, showing continued commercial adoption. Gross margin of 74.3% suggests strong pricing power and favorable product economics.
What are the risks of investing in AXGN?
Claude: Significant operating losses (-$2.8M) and net losses (-$19.6M) with no visible profitability inflection point. Negative free cash flow (-$1.2M) despite 20% revenue growth indicates broken unit economics or severely uncontrolled cost structure. ChatGPT: Net income deteriorated 57.6% YoY, showing profitability remains fragile. Operating margin is still negative at -3.5%, so scale has not yet translated into sustained earnings.
What is AXGN's revenue and growth?
Axogen, Inc. reported revenue of $61.5M.
Does AXGN pay dividends?
Axogen, Inc. does not currently pay dividends.
Where can I find AXGN SEC filings?
Official SEC filings for Axogen, Inc. (CIK: 0000805928) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AXGN's EPS?
Axogen, Inc. has a diluted EPS of $-0.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AXGN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Axogen, Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AXGN stock overvalued or undervalued?
Valuation metrics for AXGN: ROE of -8.0% (sector avg: 15%), net margin of -31.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AXGN's AI grade for 2026?
Our dual AI analysis gives Axogen, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AXGN's free cash flow?
Axogen, Inc.'s operating cash flow is $1.6M, with capital expenditures of $2.8M. FCF margin is -2.0%.
How does AXGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -31.9% (avg: 12%), ROE -8.0% (avg: 15%), current ratio 7.10 (avg: 2).